Lecture Details - Overview

Back to Lectures

Accreditation and Credit Designation

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Rapid Reviews in Oncology: Emerging Options in the Treatment of Breast Cancer June 2008

Jun 25-Jul 2, 2008, Dallas, TX

1.5 AMA PRA Category 1 Credits™
Release Date: July 02, 2008
Expiration Date: July 02, 2009

Lecture Overview

Summary and Purpose

Rapid Reviews in Oncology: Emerging Options in the Treatment of Breast Cancer is a series of CME-designated conferences that focus on cutting-edge clinical updates on the management of patients with breast cancer. The series, which is intended for practicing community oncologists, includes didactic lectures followed by an interactive discussion of cases and clinical questions with the faculty of nationally recognized thought leaders.

These conferences are nationally broadcast programs designed to simultaneously update oncologists on current and late-breaking data delivered via satellite to an audience of oncologists through a network of private dining rooms located in restaurants throughout the country. The meetings will feature interactive participation with each site, including live questions beamed in from locations throughout the network.

Target Audience

This educational program is directed toward medical oncologists, including fellows in training, involved in the treatment of patients with breast cancers. Oncology nurses, oncology physician assistants, and pharmacists who are interested in the treatment of cancer are also invited to attend.

Learning Objectives

Upon completion of this educational activity, you should be able to:

  • Evaluate the activity of epothilones, alternative taxane formulations, and other novel microtubule-targeting agents, alone or in combination regimens, in patients with relapsed/refractory metastatic breast cancer
  • Assess the efficacy and safety of antiangiogenic therapies with taxanes in newly diagnosed metastatic breast cancer
  • Discuss antiangiogenic agents undergoing clinical investigation in metastatic breast cancer
  • Evaluate current data on the efficacy and safety of nonanthracycline regimens in the adjuvant treatment of breast cancer

Instructions for Participation

  1. Read the following information before beginning the educational activity.
  2. View and study all Flash video presentations.
  3. Complete the CME test.
  4. Answer the evaluation questions.
  5. After successful completion of the CME test and evaluation,
    you will receive your certificate of credit online.
  • CME credit will be granted for online participation only.

Complete the evaluation and CME test by July 2, 2009 to receive your certificate of credit online.

Please scroll to the bottom and accept the CME Activity Terms in order to continue:

Disclosure Policy

It is the policy of Physicians' Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians' Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians' Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is delineated by the faculty during the presentation. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

This educational activity is supported by a grant from: Bristol-Myers Squibb and Genentech BioOncology .

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

Macintosh Users
Compatible Web browsers include

DisclaimerThe views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the faculty and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within. Privacy Policy

Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2008 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, Rapid Reviews in Oncology: Emerging Options in the Treatment of Breast Cancer
Physicians' Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3456
Fax: (214) 367-3304
E-mail: editor@pergrouplp.com

Educational Grants

An educational grant for this activity was provided by:


  1. Genentech BioOncology
  2. Bristol-Myers Squibb